PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15915006

Modulite: a simple solution to a difficult problem.

D A Lewis·D Ganderton·B J Meakin·G Brambilla
View original source ↗Export metadata ↓

Abstract

The development of HFA-based pMDIs has proved difficult due to differences in the physico-chemical properties of CFC and HFA propellants. However, the development of solution formulations instead of suspensions has provided a way to formulate products whose cloud characteristics can be modulated in a controlled manner by permitting different formulation and device hardware variables. The new approach has proved successful in formulating several different drugs including steroids and has now been applied to developing a formoterol Modulite solution formulation characterized by good chemical stability, delivery performance, and clinical results.

Explore related subjects

Aerosol PropellantsBronchodilator AgentsChemistry, PharmaceuticalDrug StabilityEthanolaminesFormoterol FumarateHumansMetered Dose InhalersTechnology, PharmaceuticalEvaluation StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D A Lewis, D Ganderton, B J Meakin, G Brambilla. 2005. Modulite: a simple solution to a difficult problem.. https://doi.org/10.1159/000083686

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Lung deposition of HFA beclomethasone dipropionate in an animal model of bronchopulmonary dysplasia.

The best delivery of a drug in ventilated neonates is obtained when using a small particle diameter solution administered via a spacer. Lung deposition of hydrofluoroalkane beclomethasone dipropionate (QVAR, 1.3 microm particles), delivered via an Aerochamber-MV15, was measured in piglets under conditions mimicking ventilated severely ill neonates (uncuffed 2.5 mm endotracheal tube; peak pressure 16 cm H2O; respiratory rate 40/min). After determining the mass and particle size distribution of the 99mTc-labeled and unlabeled drug, three lung deposition studies were performed: after 1 h of ventilation (controls, n = 18), after 48 h aggressive ventilation inducing an acute lung injury (nine piglets out of the controls), and after increasing the pressure to 24 cm H2O during drug delivery (five piglets out of the nine with acute lung injury). All piglets were then killed for lung histology. Results (median, range), expressed as a percentage of the delivered dose, were compared using an inferential or the Friedman test. While lung deposition was low, it was greater (p = 0.003) in controls (2.66%, 0.50-7.70) than in piglets with histologically confirmed acute lung injury (0.26%, 0.06-1.28) or under a high-pressure ventilation (1.01%, 0.30-2.15). Lung deposition of QVAR in an animal model of ventilated neonates is low, variable, and dramatically affected by lung injury.

Aerosol Propellants↗
PubMed2007

Evaluation of metered dose inhaler (MDI) formulations of ciclosporin.

Our purpose was to evaluate metered dose inhaler (MDI) formulations of cyclosporin (cyclosporine) for aerodynamic properties, chemical stability and bioactivity. Ciclosporin formulations (0.1, 0.5 and 1.0% w/w) were prepared in hydrofluoroalkane (HFA) propellants (134a and 227) containing 3 and 6% ethanol. Aerodynamic properties of the MDI formulations were analysed using an eight-stage Andersen cascade impactor and respirable mass and non-respirable mass, mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were determined from the impaction profiles. The chemical stability of 0.1% ciclosporin in HFA 227 containing 3% ethanol formulation stored at room temperature and 40 degrees C was evaluated by HPLC at 0, 14, 30 and 90 days. The bioactivity of ciclosporin MDI formulations was evaluated by determining the ciclosporin-mediated inhibition of interleukin-2 (IL-2) release from human Jurkat cells stimulated with phorbol 12-myristate 13-acetate (PMA). As ethanol concentration increased from 3 to 6%, respirable mass decreased from 2.3 mg per five actuations to 0.04 mg per five actuations for HFA 227 formulations, and from 1.5 mg to 0.09 mg per five actuations for HFA 134a formulations. The MMAD for both HFA 134a and 227 formulations increased with an increase in ciclosporin concentration. HPLC analysis showed ciclosporin to be extremely stable in HFA 227 at room temperature and 40 degrees C. Stimulation of Jurkat cells with PMA released significant amounts of IL-2, which was inhibited by ciclosporin in a dose-dependent manner. This study shows the feasibility of developing chemically stable and bioactive HFA-based MDI formulations of ciclosporin.

Aerosol Propellants↗
PubMed2006

A study of kinetic behaviours of the effective centralite/stabilizer consumption reaction of propellants using a multi-temperature artificial accelerated ageing test.

Using a multi-temperature artificial ageing testing apparatus and a standard method of determining the effective centralite/stabilizer content, the effective centralite/stabilizer content for varying time period in propellants heated at 95 degrees C, 90 degrees C, 85 degrees C, 75 degrees C and 65 degrees C was measured. Bethelot's equation and Semenov's equation in the temperature range of 65-95 degrees C for 81 propellants were established. The safe storage life at 30 degrees C, kinetic parameters [the apparent activation energy (E) and the pre-exponential constant (A)] and isolife temperatures obtained from the established equations and the activation energy (E(alpha=0.5)) obtained by integral isoconversional non-linear method for 81 propellants: single-base gun propellants (DF-01-DF-16), double-base gun propellants (SF-01-SF-13), tri-base gun propellants (SG-01-SG-02), nitramine gun propellants (GSF-01-GSF-18), double-base propellants (ST-01-ST-13), and composite modified double-base propellants (GST-01-GST-19), were given. Information was obtained on the effective centralite/stabilizer consumption reaction and the kinetic compensation effect.

Aerosol Propellants↗